GLP-3 Reta

Batch COA: In Progress

This batch is currently undergoing conformity testing at Vanguard Laboratory. The full Certificate of Analysis — covering identity, purity, net content, endotoxins, heavy metals, and sterility — will be published here and linked via QR code on each vial upon completion.

We don't ship product before results are in. When the COA is live, you'll find it here and on our COA Library.

• 1. Overview
• 2. Biochemical Characteristics
• 3. Research Applications
• 4. Pathway / Mechanistic Context
• 5. Preclinical Research Summary
• 6. Form & Analytical Testing
• 7. Referenced Citations
• 8. RUO Disclaimer

Overview

GLP-3 Reta (LY3437943) is a synthetic 39-amino acid peptide developed for laboratory investigation of multi-receptor metabolic signaling pathways. It functions as a triple agonist at the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R) — a receptor combination that makes it a useful research tool for studying coordinated energy regulation, lipid metabolism, and glycemic signaling within a single compound.

In research settings, GLP-3 Reta is used as a molecular probe to examine how simultaneous activation of these three pathways influences downstream metabolic outcomes in controlled experimental models. Its distinct receptor profile sets it apart from single-agonist (GLP-1 only) and dual-agonist (GIP/GLP-1) compounds studied in comparable research contexts.

Biochemical Characteristics

Chemical Formula: C₂₂₁H₃₄₂N₄₆O₆₈

Molecular Weight: 4731.33 g/mol

CAS No.: 2381089-83-2

PubChem CID: 145069547

Synonyms: LY3437943, Reta

GLP-3 Reta is structured on a GIP peptide backbone conjugated to a C20 fatty diacid moiety, which supports extended half-life characteristics observed in experimental systems. Published in vitro binding studies report EC50 values of 5.79 nM at GCGR, 0.0643 nM at GIPR, and 0.775 nM at GLP-1R. These binding affinities reflect the compound's differential potency across its three target receptors.

Source: PubChem

Research Applications

• Multi-receptor agonism studies examining simultaneous GCGR, GIPR, and GLP-1R activation
• Metabolic signaling cascade research in lipid utilization and glucose homeostasis models
• Receptor selectivity and binding affinity comparisons against single and dual agonist compounds
• Energy expenditure pathway investigation in preclinical models
• Adipose tissue biology and lipid metabolism studies
• Comparative pharmacology research examining incretin-based receptor interactions

All applications are restricted to non-clinical laboratory research environments.

Pathway / Mechanistic Context

GLP-3 Reta's triple-agonist profile targets three GPCRs with distinct but overlapping roles in metabolic regulation. GLP-1R activation is associated with glucose-dependent insulin secretion and reduced gastric motility in published research. GIPR activation has been examined in the context of insulin potentiation and adipocyte signaling. GCGR activation influences hepatic glucose production, fatty acid oxidation, and thermogenesis pathways.

The simultaneous engagement of all three receptors creates a convergent signaling environment not achievable with mono- or dual-agonist tools. Published experimental models have examined how this convergence affects downstream effectors including cAMP accumulation, AMPK signaling, and transcriptional programs related to lipid and glucose metabolism.

Triple-receptor metabolic signaling overview
Source: Journal Name

-->

Preclinical Research Summary

Preclinical investigations with Retatrutide have been conducted across in vitro receptor binding assays and in vivo rodent models. Published work from Eli Lilly researchers (Coskun et al., 2022) characterized the compound's receptor engagement profile and reported data on receptor activation kinetics, binding kinetics, and downstream signaling readouts across all three target receptors.

Additional experimental work has examined Retatrutide in models focused on adipose tissue biology, hepatic lipid handling, and energy balance, with investigators noting the compound's distinct multi-pathway profile relative to single-mechanism comparators. Phase 1 and Phase 2 clinical trial data has been published examining pharmacokinetics and receptor engagement in human subjects, providing reference data for research contexts.

Form & Analytical Testing

GLP-3 Reta is supplied as research-grade lyophilized powder. Each batch undergoes conformity testing through Vanguard Laboratory using a 5-vial testing protocol. Testing covers identity verification, purity analysis (≥98% via HPLC), net content verification (30mg confirmed), endotoxin levels, heavy metals, and sterility. Full COA documents are published on our COA Library and linked via QR code on each vial.

This is conformity-level testing — not a single-vial spot check. It's what separates a real quality commitment from a checkbox.

Referenced Citations

1. Coskun T et al., "LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist for glycemic control and weight loss," Cell Metab, 2022 34(9):1353–1369.
2. Urva S et al., "LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes," Diabetes, 2024 73(3):486–496.
3. Jall S et al., "Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice," Mol Metab, 2017 6(8):440–451.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

RUO Disclaimer

The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals.

This product is not a drug, food, or cosmetic and may not be misbranded, misused, or mislabeled as a drug, food, or cosmetic. No statements on this website have been evaluated by the FDA. You must be 21 years or older to purchase.